Monitoring is frequently the largest single service line in a CRO proposal, and it is also the line most shaped by assumptions the sponsor never stated. If you ask five CROs to propose a monitoring approach, you will receive five different strategies at five different prices, and comparing them becomes guesswork. Deciding the outline of your monitoring strategy before the RFP, including the mix of on-site, remote, and centralized activities, lets every CRO price the same approach and lets you see real differences in efficiency and quality.
Why does monitoring strategy drive so much of the budget?
The arithmetic adds up quickly. Consider 30 sites, each visited on site every six weeks during an 18-month treatment period. That is roughly 12 visits per site, or about 360 visits, each with preparation, travel, time on site, a visit report, and follow-up. Change the interval to every ten weeks with remote review in between, and the visit count falls by approximately 40 percent. The study may be just as well monitored, or better, if the remote and centralized activities are well designed.
What decisions belong in a monitoring strategy?
At a minimum, the strategy should settle five things:
The mix of on-site, remote, and centralized monitoring, and what each one covers
The approach to source data verification and source data review, including which data receive full verification
On-site visit frequency, and the triggers that prompt an additional visit
The central monitoring methods, key risk indicators, and how often they are reviewed
Who does what, including any review the sponsor performs directly
What does ICH E6(R3) expect?
ICH E6(R3), adopted in January 2025, asks sponsors to take a risk-proportionate approach to quality and oversight, focused on the factors critical to participant safety and the reliability of trial results. It does not prescribe a single monitoring model. Instead, it expects the sponsor to choose methods that fit the risks of the specific trial and to document the rationale. A strategy defined before the RFP is a practical way to show that the choice was made by the sponsor, on purpose, for this study.
How do you decide what is right for your study?
Start from a risk assessment. A first-in-human study with intensive safety monitoring at a few experienced units warrants a different approach than a large outpatient study across 60 community sites. Consider the complexity of the protocol, the safety profile of the investigational product, the experience of the likely sites, the nature of the primary endpoint, and whether data are captured electronically at the source. Studies with electronic source data and electronic patient-reported outcomes often support more remote and central review.
How should the RFP describe the strategy?
Give CROs concrete assumptions to price. For example: an on-site visit after the first participant is enrolled at each site, then every eight weeks or when triggered; remote review of key data between visits; targeted verification of critical data such as eligibility, primary endpoint, and serious adverse events; and monthly central statistical monitoring. Then invite each CRO to price your strategy and, separately, to propose an alternative if it would recommend one. You get comparable numbers and the benefit of each CRO's expertise.
What should you watch for in the proposals?
Look for visit counts that differ from your assumptions without explanation, descriptions of a risk-based approach that contain no numbers, and proposals with no separate cost for central monitoring, which may mean it has not been included. Ask each CRO how its monitors and central monitoring team share findings, because the value of a hybrid approach depends on that connection.
Who on the sponsor side should own monitoring oversight?
Name one person, even in a very small company. That person reviews visit reports on a sampling basis, follows the key risk indicators, and decides with the CRO when a trigger should prompt an extra visit or a change in approach. A monitoring strategy is a living document, and the study will teach you things the risk assessment could not predict. Plan to revisit the strategy formally after the first five or six sites are active, and again at roughly the midpoint of enrollment.
Keep reading: Reading a Monitoring Visit Report Like an Inspector
